ALT Altimmune Inc.

2.97
-0.02  -1%
Previous Close 2.99
Open 3
Price To Book 0.66
Market Cap 25976856
Shares 8,755,260
Volume 41,082
Short Ratio
Av. Daily Volume 501,367

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 trial met primary endpoint. Phase 2 planned.
HepTCell
Hepatitis B
Phase 2 additional data released September 4, 2018.
NasoVAX
Flu vaccine
Phase 1 data showed limited response.
NASOSHIELD
Anthrax